AstraZeneca Pharma India Limited Annual Report FY2026
AstraZeneca Pharma India Limited Annual Report FY2026
Quality Scores
Latest Quarterly Earnings Summary
Loading latest quarter…
AI Summary
AstraZeneca Pharma India Limited (AZPIL) exhibits the characteristics of a high-quality pharmaceutical entity driven by its parent company’s global R&D pipeline. The business has undergone a significant transformation from a loss-making entity in FY15 to a highly profitable organization with a sales CAGR of 15% over 10 years, accelerating to 31% over the last three years. The business model is increasingly tilted toward high-margin segments like Oncology and CVRM, which has structurally improved the return profile. With a ROCE consistently near 30% and zero long-term debt, the financial…
Key Changes in FY2026
The business has undergone a significant transformation from a legacy pharmaceutical player to an innovation-led leader in chronic disease segments. Over the last decade, AZPIL has pivoted its portfolio toward high-growth areas including Cardiovascular, Renal, Metabolism (CVRM), and Oncology. The recent approval for Enhertu for breast cancer indications highlights a steady move toward biologics and complex specialty medicines. Strategic shift is evident in the margin expansion seen from FY2015 (negative margins) to the current stable double-digit OPMs. The company is successfully leveraging the global parent's pipeline to introduce 'First-in-Class' and 'Best-in-Class' therapies in India. This evolution reflects a transition from a general medicine focus to a specialized,…
Management Commentary
Management execution has been consistent, successfully pivoting the company towards high-growth specialty segments like Oncology. There is high transparency in disclosures, evidenced by the regular conduction of AGMs and detailed corporate presentations. The alignment with AstraZeneca PLC (UK) ensures access to a global best-in-class product portfolio and clinical research. The leadership has successfully navigated the complex Indian regulatory environment while maintaining a 75% promoter holding. However, the recent demand notices from the NPPA regarding overcharging for Symbicort and Betaloc suggest an ongoing struggle with price control regulations. Overall, management has demonstrated a clear ability to drive profitable growth in a competitive landscape.
Financial Highlights
The financial trajectory demonstrates a significant turnaround from an operating loss of INR 11 Cr in FY15 to an operating profit of INR 262 Cr in FY26. Revenue growth has been robust, particularly in the last 24 months, driven by volume growth in the core portfolio. EBITDA margins have stabilized in the 12-16% range, showing resilience despite rising expenses associated with product launches. The company maintains a high-quality balance sheet with negative net debt and a very high current ratio. ROE has stabilized at an impressive 23%, reflecting efficient utilization of shareholder funds. The recent surge in sales to INR 2,276 Cr in FY26 suggests the business is successfully scaling its specialty presence in the Indian market.
Major Opportunities
- MNC parentage with AstraZeneca UK plc (75%)
- Asset-light business model with high ROCE
- Strong 10-year PAT CAGR of 43%
Major Risks
- High regulatory risk from NPPA overcharging notices
- Significant working capital stretch in FY26
- Sharp rise in Inventory Days to 272
About This Annual Report
The AstraZeneca Pharma India Limited FY2026 Annual Report is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis (MD&A), audited financial statements, director's report, corporate governance report, auditor's report, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This page consolidates the official PDF and an AI-generated summary so investors can quickly grasp what changed vs. prior years — sales growth, margin trend, cash flow quality, capex, dividends and management outlook — without having to read the entire filing.
Why Use AI?
- Summarises hundreds of pages into a focused executive briefing
- Identifies year-on-year key changes automatically
- Extracts management commentary and tone
- Highlights top risks and opportunities
- Compares business evolution vs. earlier years
- Answers your questions in plain English via Ask AI
Frequently Asked Questions
Related Research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.